Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
75.63
+0.46 (0.61%)
Apr 13, 2026, 11:56 AM EDT - Market open
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,402 employees as of December 31, 2025. The number of employees increased by 333 or 31.15% compared to the previous year.
Employees
1,402
Change (1Y)
333
Growth (1Y)
31.15%
Revenue / Employee
$673,118
Profits / Employee
-$272,031
Market Cap
12.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,402 | 333 | 31.15% |
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
IONS News
- 14 days ago - FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - GlobeNewsWire
- 17 days ago - Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga
- 21 days ago - Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire
- 5 weeks ago - Ionis announces changes to Board of Directors - Business Wire
- 5 weeks ago - Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - GlobeNewsWire
- 6 weeks ago - Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting - Business Wire
- 6 weeks ago - Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) - Business Wire
- 6 weeks ago - Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug - Benzinga